BBIO - BridgeBio Pharma, Inc.
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
Sales of BridgeBio's cutting-edge heart drug nearly tripled year over year in the second quarter. The biotech also has other medications in late-stage development that are packed with potential.
- The transaction supports the evolution of the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P.
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.
BridgeBio Pharma (NASDAQ: BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year. Chief Executive Officer Neil Kumar described the period as a transition point for the company, citing the commercial
PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby's U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO's $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline investment.
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year.
California State Teachers Retirement System boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 23.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 165,703 shares of the company's stock after acquiring an additional 31,797 shares during the quarter.
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double this year.
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.